RxDoctor Payments Data

Shripal Makim, MD

Psychiatry · Lawrenceville, GANPI 1104900141

Payments from drug & device makers

$4,585in general payments, 2019–2025

Across 199 payments — averaging $23.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neos Therapeutics, LP$759
  • Takeda Pharmaceuticals U.S.A., Inc.$467
  • Alkermes, Inc.$408
  • Neurocrine Biosciences, Inc.$385
  • AbbVie$367
  • Johnson & Johnson$341
  • plus $2K from 16 others

What the payments were for

  • Consulting fees$55012%
  • Travel & lodging$371%
  • Food & beverage$3,99887%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,585 in reported general payments places this provider in the 85th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$76,564
Medicare patients
140
Services billed
946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine16$91,653
Invega SustennaPaliperidone Palmitate12$47,443
VraylarCariprazine Hcl29$43,254
Aripiprazole98$7,814
Oxcarbazepine90$7,604
Desvenlafaxine Succinate ErDesvenlafaxine Succinate103$4,453
Lisdexamfetamine Dimesylate13$4,147
Bupropion XlBupropion Hcl232$3,975
Perphenazine48$3,364
Vilazodone Hcl49$3,259
Olanzapine87$3,070
Venlafaxine Hcl ErVenlafaxine Hcl192$2,993
Trazodone Hcl419$2,661
Atomoxetine Hcl19$2,570
Escitalopram Oxalate276$2,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$130$91,65316 claims
Johnson & JohnsonInvega Sustenna$341$47,44312 claims
AbbVieVraylar$367$43,25429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Lawrenceville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →